TLXTelix Pharmaceuticals Limited
Price
+12%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growing in the filings, the market undecided.
We are a global, commercial-stage biopharmaceutical company, focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. We are committed to the principles of precision oncology. By this we mean developing both therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as ‘theranostics’.
In the company’s own words · 20-F filed Feb 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $804M (+56% year on year) and net income −$7.1M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry